Natural killer/T-cell lymphoma (NKTCL) is an aggressive non-Hodgkin lymphoma that has been facing limited success with conventional treatments, urging for the discovery of alternative strategies. Recent studies including ours have revealed that EZH2 and JAK-STAT signalling pathways are key contributors to NKTCL pathogenesis. In particular, we found that EZH2 is overexpressed and directly transcriptionally activates the gene to confer growth advantage. codes for cyclin D1, which complexes with CDK4/6 to promote G1 to S phase transition. Therefore in this study we investigated whether inhibiting both JAK1/2 and CDK4/6, using LEE011 and ruxolitinib respectively is effective in NKTL. We first demonstrate that separate LEE011 and ruxolitinib treatment is sufficient to cause growth inhibition of NKTCL cells. More importantly, we found that there is synergistic growth inhibitory effects on NKTCL cells with combination treatment of LEE011 and ruxolitinib. The results obtained shows that the targeting of both CDK4/6 and JAK1/2 are promising to develop better treatment alternatives for NKTCL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112754 | PMC |
| http://dx.doi.org/10.18632/oncotarget.25835 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clarifying new molecular subtyping and precise treatment of melanoma based on disulfidptosis-related lncRNA signature.
Eur J Med Res
September 2024
Dermatology Center, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.
Article Synopsis
- Disulfidptosis is a new type of programmed cell death linked to the immune environment in cancer, particularly affecting melanoma, and its connection with long non-coding RNA (lncRNA) is still being explored.! -
- A prognostic model using disulfidptosis-related lncRNA from melanoma data reveals different risk groups and immune statuses, showing that high-risk patients experience significant immune suppression.! -
- The study classifies melanoma into distinct subgroups based on their immune profile and drug sensitivity, providing insights for improving personalized treatment options and highlighting targets for further research.!
Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors.
Breast Cancer Res Treat
April 2024
Department of Dermatology, Stanford University, Palo Alto, CA, USA.
Article Synopsis
- This study investigates vitiligo-like skin lesions in patients undergoing treatment with CDK4/6 inhibitors for metastatic breast cancer, noting their prevalence and impact on quality of life.* -
- A retrospective review involved ten patients from five institutions, revealing that the median age was 55 and that lesions primarily developed on sun-exposed areas after about 10 months of treatment.* -
- Although multiple treatments were trialed with limited success, ruxolitinib cream showed slight repigmentation in one patient, emphasizing the need for collaboration between oncologists and dermatologists for better management.*
Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.
Clin Cancer Res
June 2021
Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
Purpose: The JAK1/2 inhibitor ruxolitinib has demonstrated significant benefits for patients with myeloproliferative neoplasms (MPN). However, patients often lose response to ruxolitinib or suffer disease progression despite therapy with ruxolitinib. These observations have prompted efforts to devise treatment strategies to improve therapeutic efficacy in combination with ruxolitinib therapy.
View Article and Find Full Text PDFProperties of FDA-approved small molecule protein kinase inhibitors.
Pharmacol Res
June 2019
Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742-8814, United States. Electronic address:
Because mutations, overexpression, and dysregulation of protein kinases play essential roles in the pathogenesis of many illnesses, this enzyme family has become one of the most important drug targets in the past 20 years. The US FDA has approved 48 small molecule protein kinase inhibitors, nearly all of which are orally effective with the exceptions of netarsudil (which is given as an eye drop) and temsirolimus (which is given intravenously). Of the 48 approved drugs, the majority (25) target receptor protein-tyrosine kinases, ten target non-receptor protein-tyrosine kinases, and 13 target protein-serine/threonine protein kinases.
View Article and Find Full Text PDFLEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL).
Oncotarget
August 2018
Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Natural killer/T-cell lymphoma (NKTCL) is an aggressive non-Hodgkin lymphoma that has been facing limited success with conventional treatments, urging for the discovery of alternative strategies. Recent studies including ours have revealed that EZH2 and JAK-STAT signalling pathways are key contributors to NKTCL pathogenesis. In particular, we found that EZH2 is overexpressed and directly transcriptionally activates the gene to confer growth advantage.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!